Quastella

Quastella Inc. is a startup from Nagoya University founded in 2019 by Yuto Takemoto, who serves as CEO. The company specializes in cell quality control, addressing inconsistencies and scalability issues inherent in traditional manual inspection methods for cell manufacturing.

The core product is Cytometa, a cloud-based platform that leverages AI and image processing for the quality evaluation of living cells. This system provides a standardized, quantitative, and data-driven assessment of cell quality during production, analyzing images from various microscopes without needing specialized equipment. It is designed to replace subjective evaluations with objective, data-driven assessments. In addition to the platform, Quastella offers tailored consulting and Proof of Concept (PoC) support to assist manufacturers in customizing the AI for their specific processes, including different culture methods, imaging tools, and cell types.

The business model is centered on providing this cell quality management platform and its associated services. The company generates revenue by offering data analysis, platform development, and consulting to its clients. Quastella serves companies in the pharmaceutical, regenerative medicine, and cosmetics industries. In July 2025, the company announced it had raised 110 million yen through a third-party allotment and a loan, with investors including Aichi Capital and epiST Ventures. This funding is intended to advance the Cytometa system and support productivity in the biomanufacturing sector.

Keywords: cell quality control, AI-powered evaluation, Cytometa, biomanufacturing, regenerative medicine, cell culture, image analysis platform, life sciences, Nagoya University startup, pharmaceutical manufacturing, quantitative cell analysis, PoC support, data-driven quality assessment, biotechnology, cell manufacturing automation, lab automation, cosmetics industry, Yuto Takemoto